Rosuvastatin Beneficial for Patients With Kidney Disease and Elevated CRP...
NEW YORK (Reuters Health) Mar 03 - In patients with moderate kidney disease and elevated high-sensitivity C-reactive protein, rosuvastatin helps reduce cardiovascular events and all-cause mortality, new research shows.
The findings stem from a secondary analysis of data from the JUPITER trial, which compared rosuvastatin to placebo for preventing first-ever cardiovascular events in men over 50 and women over 60.
The original study involved nearly 18,000 participants. The post hoc analysis, reported in the March 23rd Journal of the American College of Cardiology, focused on 3267 subjects with moderate chronic kidney disease at baseline, as defined by an estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m2. At baseline, they had low density lipoprotein cholesterol levels below 130 mg/dL but high-sensitivity C-reactive protein levels of 2 mg/L or higher.
Lead author Dr. Paul M. Ridker, from Brigham and Women's Hospital, Boston, and colleagues report that over a median follow-up period of 1.9 years, the men and women with moderate chronic renal disease were 54% more likely to experience a vascular event, compared to the 14,528 JUPITER participants with normal renal function (p = 0.0002).
In patients with moderate chronic kidney disease, rosuvastatin cut the rate of the primary endpoint (myocardial infarction, angina hospitalization, revascularization, or cardiovascular death) to 1.08 per 100 person-years, from the 1.95 per 100 person-years seen with placebo (hazard ratio, 0.55; p = 0.002). In addition, use of the drug reduced all-cause mortality from 1.53 to 0.85 per 100 person-years (HR 0.56, p = 0.005).
Compared to patients in the placebo group, patients in the rosuvastatin group had slightly improved renal function at 12 months.
Rosuvastatin had similar effects on cholesterol and C-reactive protein levels in patients with and without kidney disease, and similar side effects.
J Am Coll Cardiol 2010.
อ่านเพิ่มเติมได้ที่ : Medscape Pharmacist (http://www.medscape.com/viewarticle/717917?src=mp&spon=44&uac=12159BG)
ไม่มีความคิดเห็น:
แสดงความคิดเห็น
หมายเหตุ: มีเพียงสมาชิกของบล็อกนี้เท่านั้นที่สามารถแสดงความคิดเห็น